2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 217-219
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Treatment Considerations, Biological Processes, Pathogenesis, Immune Mechanism, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

345 Endothelial Piezo1 activates a calpain-GSK3β pathway that suppresses NF‑κB and thrombosis

Kelsey D Sack, MD, PhD, Emily York2, Calum MacRae, MD, PhD3, Robert Flaumenhaft, MD4
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 Brigham & Womens, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Endothelial dysfunction and alterations in blood flow are two components of Virchow’s triad that synergize with one another to promote thrombosis. Yet the underlying endothelial mechanisms mediating this synergy are poorly understood. To address this issue, we evaluated the role of Piezo1, a mechanosensitive Ca2+ channel abundant in endothelium, in the prothrombotic transformation of the endothelium. In static conditions, pharmacologic Piezo1 activation of HUVECs by the Piezo1 agonist Yoda1 reduced induction of thrombin generation by inflammatory stimuli including LPS, TNFα, and poly(IC) to 0.17, 0.10, and 0.24-fold of TNFα only (p < 0.0001) and reduced FXa generation to 0.22, 0.15, and 0.31 of TNFα only (p<0.001), respectively. The results were generalizable with similar attenuation of TNFα-induced FXa generation (0.02-fold of TNFα only, p < 0.001) in HMVEC-L. Under physiological laminar flow, Piezo1 knockdown increased endothelial tissue factor (2.3-fold, p < 0.003) expression and FXa generation (8.8-fold, p < 0.05), whereas pharmacologic Piezo1 activation reduced tissue factor expression (0.01-fold of TNFα only p< 0.015) and procoagulant activity (FXa 0.03 of TNFα only, p < 0.002 ).

To better understand how Piezo1 mediates its antithrombotic effect, we performed a small molecule screen to identify inhibitors that reversed Piezo1-mediated protection from TNF-α–induced factor Xa (FXa) activity. Prolonged pharmacologic inhibition of glycogen synthase kinase 3β (GSK3β) with BIO – an allosteric antagonist - completely reversed Piezo1-mediated suppression of FXa generation. In contrast, the catalytic GSK3 inhibitor SB216763 produced only partial reversal of the Piezo1-mediated antithrombotic phenotype. Piezo1 activation increased inhibitory GSK3β Ser9 phosphorylation (2-fold, p < 0.009 at 5 minutes and 2.2-fold, p < 0.003 at 10 minutes) and induced the appearance of truncated GSK3β species (2.8-fold increase at 60 minutes, p<0.003), consistent with proteolytic processing. To distinguish between the relative contributions of inhibitory GSK3β Ser9 phosphorylation and proteolytic processing of GSK3β, we first evaluated the effect of inhibition of Ser9 phosphorylation. Pharmacologic AKT inhibition reduced Ser9 phosphorylation to baseline, but did not reverse Piezo1-mediated protection. In contrast, knockdown of the Ca2+-sensitive protease calpain-2 decreased the formation of truncated GSK3β species to baseline and reversed the protective effects of Piezo1 activation on FXa generation. Similar findings were observed following pharmacologic calpain inhibition with PD150606. These findings linked GSK3β processing in the protective effect of Piezo1.

NF-κB signaling is a key driver of inflammation-induced endothelial dysfunction and can be modulated by GSK3β activity. To understand how Piezo1 signaling affects TNFα-mediated endothelial NF-κB activation, we evaluated the kinetics of NF-κB in the presence and absence of Piezo1 activation. Piezo1 activation did not prevent the initial phosphorylation of the NF-κB p65 subunit, but significantly attenuated sustained NF-κB activation, reducing p-p65 levels (0.4-fold of TNFα only, p< 0.05) at 60 minutes and preventing re-accumulation of IκBα. Calpain-2 knockdown reversed Piezo1-mediated impacts on NF-κB regulation, implicating calpain-dependent GSK3β remodeling as a key downstream effector of Piezo1 signaling. Inhibition of calpain-2 using PD150606 showed a similar effect, further linking calpain to Piezo1 signaling.

To evaluate the physiologic significance of these findings, we studied a murine laser-injury thrombosis model. Piezo1 activation reduced platelet accumulation (0.51-fold, p < 0.05) and fibrin deposition (0.42-fold, p < 0.05) compared with vehicle-treated controls. Endothelial cell-specific knockout of Piezo1 reversed the effect of Yoda1 on thrombosis.

These studies show that endothelial Piezo1 activation suppresses thromboinflammatory signaling and limits thrombus formation through a calpain-dependent GSK3β signaling axis. Rather than preventing initial NF-κB activation, Piezo1 promotes resolution of TNF-α–induced inflammatory signaling through calpain-mediated remodeling of GSK3β. These findings identify a previously unrecognized Piezo1–calpain–GSK3β pathway that restrains endothelial inflammation and thrombosis and may represent a novel therapeutic target in thromboinflammatory disease.

Kelsey D Sack, MD, PhD: Takeda - Consultancy (Includes expert testimony)